Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).

被引：0
|
作者：
Lalani, Aly-Khan A.
Swaminath, Anand
Pond, Gregory Russell
Morgan, Scott C.
Azad, Arun
Chu, William
Kapoor, Anil
Bonert, Michael
Bramson, Jonathan L.
Surette, Michael G.
Bosse, Dominick
Siva, Shankar
Bjarnason, Georg A.
Gopaul, Darin
Basappa, Naveen S.
Wright, Jim
Hotte, Sebastien J.
机构：
[1] McMaster Univ, Dept Oncol, Juravinski Canc Ctr, Hamilton, ON, Canada
[2] McMaster Univ, Ontario Clin Oncol Grp, Hamilton, ON, Canada
[3] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[4] Peter MacCallum Canc Ctr, Div Med Oncol, Melbourne, Vic, Australia
[5] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[6] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[7] St Josephs Healthcare Hamilton, Dept Pathol, Hamilton, ON, Canada
[8] McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada
[9] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada
[10] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[11] Grand River Hosp, Kitchener, ON, Canada
[12] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS750
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
    Masini, Cristina
    Iotti, Cinzia
    De Giorgi, Ugo
    Bellia, Roberto Salvatore
    Buti, Sebastiano
    Salaroli, Francesco
    Zampiva, Ilaria
    Mazzarotto, Renzo
    Mucciarini, Claudia
    Vitale, Maria Giuseppa
    Bruni, Alessio
    Lohr, Frank
    Procopio, Giuseppe
    Caffo, Orazio
    Nole, Franco
    Morelli, Franco
    Baier, Susanne
    Buttigliero, Consuelo
    Ciammella, Patrizia
    Timon, Giorgia
    Fantinel, Emanuela
    Carlinfante, Gabriele
    Berselli, Annalisa
    Pinto, Carmine
    EUROPEAN UROLOGY, 2022, 81 (03) : 274 - 282
  • [32] Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
    Grabbert, Markus
    Grosu, Anca L.
    Zamboglou, Constantinos
    Gratzke, Christian
    EUROPEAN UROLOGY, 2022, 81 (06) : 622 - 622
  • [33] Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review
    Ingrosso, Gianluca
    Becherini, Carlotta
    Francolini, Giulio
    Lancia, Andrea
    Ali, Emanuele
    Caini, Saverio
    Teriaca, Maria Ausilia
    Marchionni, Alessandro
    Filippi, Andrea Riccardo
    Livi, Lorenzo
    Sanguineti, Giuseppe
    Aristei, Cynthia
    Detti, Beatrice
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 159
  • [34] Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition
    Fischer, R. N.
    Abdulla, D.
    Michels, S.
    Nogova, L.
    Brandes, V
    Scheffler, M.
    Schaeffer, S.
    Scheel, A.
    Thurat, M.
    Vehreschild, M.
    Thomas, R.
    von Bergwelt-Baildon, M.
    Buettner, R.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 92 - 93
  • [35] A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
    Bouligny, Ian M.
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Daver, Naval
    Jabbour, Elias
    Valero, Yesid Alvarado
    Dinardo, Courtney D.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Kadia, Tapan M.
    Masarova, Lucia
    Takahashi, Koichi
    Andreeff, Michael
    Bazinet, Alexandre
    Yang, Hui
    Kanagal-Shamanna, Rashmi
    Pierce, Sherry
    Meyer, Meghan Anne
    Huang, Xuelin
    Garcia-Manero, Guillermo
    BLOOD, 2024, 144 : 3212 - 3214
  • [36] A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer
    Liu, J. F.
    Herold, C.
    Luo, W.
    Penson, R.
    Horowitz, N.
    Konstantinopoulos, P.
    Castro, C.
    Curtis, J.
    Matulonis, U. A.
    Cannistra, S.
    Dizon, D. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS
    Bang, Andrew
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S26 - S27
  • [38] Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
    Bang, A.
    Mahmood, U.
    Chen, Y. H.
    Mak, R. H.
    Lorch, J.
    Hanna, G. J.
    Sridharan, V.
    Busse, P. M.
    Willers, H.
    Mamon, H. J.
    Yoo, H. J.
    Pai, S. I.
    Wirth, L.
    Haddad, R. I.
    Chau, N.
    Schoenfeld, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E363 - E363
  • [39] Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney
    Watanabe, Kyohei
    Sugiyama, Takayuki
    Otsuka, Atsushi
    Miyake, Hideaki
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2020, 9 (01) : 32 - 35
  • [40] Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney
    Kyohei Watanabe
    Takayuki Sugiyama
    Atsushi Otsuka
    Hideaki Miyake
    International Cancer Conference Journal, 2020, 9 : 32 - 35
12345